Table 2. Adjusted Prescribing Outcomesa.
| Usual care | Nudge | |||
|---|---|---|---|---|
| Patient | Clinician | Combined | ||
| Unadjusted prescribing rates | ||||
| Preintervention, No./total No. (%) | 105/1876 (5.6) | 97/2022 (4.8) | 104/1723 (6.0) | 82/1752 (4.7) |
| Intervention, No./total No. (%) | 75/1032 (7.3) | 100/1181 (8.5) | 128/981 (13.0) | 145/937 (15.5) |
| Unadjusted difference in percentage points from pre- to postintervention (95% CI) | 1.7 (0.1 to 3.2) | 3.7 (2.1 to 5.2) | 7.0 (5.1 to 9.0) | 10.8 (8.8 to 12.8) |
| Main adjusted model b | ||||
| Difference in percentage points relative to usual care (95% CI) | NA | 0.9 (−0.8 to 2.5) | 5.5 (3.4 to 7.8) | 7.2 (5.1 to 9.1) |
| P value relative to usual care | NA | .32 | .01 | .001 |
| Fully adjusted model c | ||||
| Difference in percentage points relative to usual care (95% CI) | NA | 0.6 (−1.1 to 2.2) | 5.5 (3.2 to 8.1) | 7.0 (4.9 to 9.0) |
| P value relative to usual care | NA | .46 | .02 | .001 |
Abbreviation: NA, not applicable.
a
Statin prescribing by the end of the day of the primary care visit.
b
Adjusted for study arm, calendar month for the intervention period, preintervention statin prescribing rates at the clinician level, and random effects at the clinician and practice level.
c
Also adjusted for patient age, sex, race and ethnicity, insurance, annual household income, and Charlson Comorbidity Index.